Michael Kishbauch - Progenics Pharmaceuticals Director
Director
Mr. Michael D. Kishbauch is no longer an Independent Director of Progenics Pharmaceuticals, Inc., October 17, 2019. Prior to his work at Achillion, Michael founded and served as President and Chief Executive Officer of OraPharma, Inc., which was a publicly traded, commercialstage pharmaceutical company focused on oral health care. OraPharma was acquired by Johnson Johnson. Michael previously held senior management positions with MedImmune, Inc. has held board positions with several other life sciences companies and continues to serve on Achillion Board. He holds an M.B.A. from the Wharton School of the University of Pennsylvania and a B.A. in biology from Wesleyan University. since 2013.
| Age | 69 |
| Tenure | 11 years |
| Professional Marks | MBA |
| Phone | 646 975-2500 |
| Web | www.progenics.com |
Progenics Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.4869) % which means that it has lost $0.4869 on every $100 spent on assets. This is way below average. Progenics Pharmaceuticals' management efficiency ratios could be used to measure how well Progenics Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 54.63 M in liabilities with Debt to Equity (D/E) ratio of 1.17, which is about average as compared to similar companies. Progenics Pharmaceuticals has a current ratio of 2.83, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Progenics Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Progenics Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Progenics Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Progenics to invest in growth at high rates of return. When we think about Progenics Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Marc McMorris | Fair Isaac | 52 | |
| Emer Daly | Ryanair Holdings PLC | 54 | |
| Carlos Ruisanchez | Cedar Fair LP | 49 | |
| Joanna Rees | Fair Isaac | 59 | |
| Thomas Klein | Cedar Fair LP | 53 | |
| Roderick McGeoch | Corporacion America Airports | 67 | |
| Michael Horgan | Ryanair Holdings PLC | 77 | |
| Greg Gianforte | Fair Isaac | 53 | |
| Eric Affeldt | Cedar Fair LP | 58 | |
| Duane White | Fair Isaac | 58 | |
| Charles McCreevy | Ryanair Holdings PLC | 67 | |
| James Osborne | Ryanair Holdings PLC | 67 | |
| John Leahy | Ryanair Holdings PLC | N/A | |
| Mike OBrien | Ryanair Holdings PLC | 73 | |
| Michael Cawley | Ryanair Holdings PLC | 63 | |
| Roisin Brennan | Ryanair Holdings PLC | 53 | |
| Stan McCarthy | Ryanair Holdings PLC | 59 | |
| Gina France | Cedar Fair LP | 62 | |
| Greg OGorman | Ryanair Holdings PLC | N/A | |
| James Kirsner | Fair Isaac | 77 | |
| Valerie Pechon | Corporacion America Airports | 44 | |
Management Performance
| Return On Equity | -1.0E-4 | |||
| Return On Asset | -0.49 |
Progenics Pharmaceuticals Leadership Team
Elected by the shareholders, the Progenics Pharmaceuticals' board of directors comprises two types of representatives: Progenics Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Progenics. The board's role is to monitor Progenics Pharmaceuticals' management team and ensure that shareholders' interests are well served. Progenics Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Progenics Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jeffrey Summer, Senior Vice President - Strategy and Performance | ||
| Patrick Fabbio, CFO and Sr. VP | ||
| Nitya Ray, Sr. VP of Manufacturing | ||
| David Scheinberg, Independent Director | ||
| Ann Assumma, Vice President - Regulatory Affairs | ||
| Peter Crowley, Independent Chairman of the Board | ||
| Michael Kishbauch, Director | ||
| Bradley Campbell, Independent Director | ||
| Karen Ferrante, Director | ||
| Huw Jones, Vice President - Commercial | ||
| Vivien Wong, Vice President - Product Development | ||
| Melissa Downs, IR Contact Officer | ||
| Benedict Osorio, Senior Vice President - Quality | ||
| Mark Baker, CEO, Director | ||
| Nicole Williams, Independent Director | ||
| Bryce Tenbarge, Vice President - Commercial |
Progenics Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Progenics Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.0E-4 | |||
| Return On Asset | -0.49 | |||
| Profit Margin | 12.67 % | |||
| Operating Margin | (171.72) % | |||
| Current Valuation | 370.66 M | |||
| Shares Outstanding | 86.6 M | |||
| Shares Owned By Insiders | 9.60 % | |||
| Shares Owned By Institutions | 76.10 % | |||
| Number Of Shares Shorted | 5.53 M | |||
| Price To Earning | (103.33) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Progenics Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Progenics Pharmaceuticals' short interest history, or implied volatility extrapolated from Progenics Pharmaceuticals options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Progenics Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Progenics Stock
If you are still planning to invest in Progenics Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Progenics Pharmaceuticals' history and understand the potential risks before investing.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |